Globus Medical to Report Third-Quarter Results on Nov. 5 After Market Close
Key Facts
Globus Medical had not reported its third-quarter 2026 results as of Oct. 31, contrary to the initial report that earnings and revenue had exceeded expectations. The company said it will report results for the quarter ended Sept. 30 after the market closes on Thursday, Nov. 5. The alleged results therefore cannot be used to explain the stock’s move in the Oct. 30 session. Shares closed at $78.05 after reaching an intraday high of $80.84, according to the investor relations record. The market is awaiting the company’s scheduled announcement to learn its third-quarter results and business performance.
The announcement date also includes a conference call to discuss performance with the investment community, starting at 4:30 p.m. Eastern Time on Nov. 5, according to the company. The call follows the release of results, allowing management to present details of performance in the quarter ended Sept. 30. The timing gives investors an opportunity to follow the company’s update on its results and revised outlook. Until the announcement, third-quarter figures remain undisclosed. The latest published quarterly performance was the company’s second-quarter 2026 results.
The company recorded net worldwide sales of $789.6 million in the second quarter of 2026, up 5.9% year over year. Sales growth was 5.6% excluding the impact of foreign exchange movements, according to the results statement. This figure is the latest published indication of the revenue trajectory ahead of the third-quarter report. Comparing the two growth rates shows the effect of currency on the nominal reading of sales during the quarter. The Nov. 5 results will be the company’s first announced update on performance since those figures.
Management attributed second-quarter growth to market-share gains across most core businesses, with notable performance from the U.S. and international spine businesses. The U.S. spine business grew 7% year over year, while the international business rose 14% on a reported basis, or 12% excluding the impact of foreign exchange. The gap between reported international business growth and growth on a constant-currency basis means exchange-rate movements affected the growth rate. The company said market-share gains covered most of its core businesses and identified these two businesses as the leading growth drivers. These details provide a benchmark for comparison when third-quarter results are released.
On earnings, the company said the year-over-year decline in diluted earnings per share under generally accepted accounting principles was primarily affected by a $110.5 million bargain purchase gain in the year-earlier 2025 quarter, related to the acquisition of Nevro. The company’s explanation links the decline to an exceptional gain in the prior-period comparison base, rather than attributing it to a specific operating factor in the current quarter. This context helps frame the earnings comparison between the two periods when the new results are published. The information available in the second-quarter statement did not include an additional figure for this item’s impact on third-quarter results. The new figures will be released with the Nov. 5 announcement.
After its second-quarter results, Globus Medical maintained its 2026 revenue outlook within a range of $3.18 billion to $3.22 billion. At the same time, it raised its outlook for adjusted diluted earnings per share, excluding items that do not conform to accounting principles, to $4.95–5.05, compared with the previous range of $4.70–4.80. The update combines an unchanged annual revenue range with a higher adjusted earnings-per-share estimate. The outlook provides a reference point ahead of the third-quarter announcement, but was issued after the second-quarter results. Management is scheduled to discuss performance with investors on its call following the results announcement on Nov. 5.